TriangleNCT01001377 · OUTCOME
Time to Treatment Failure
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
What was measured
Time to treatment failure (TTF) is the time from randomization date to date that the decision was made to end the treatment period for any reason; participants who remained in the treatment period at the time of analysis were censored at the date of the last on-study assessment.
Analysis population: Primary analysis set
Groups in this outcome
Cetuximab
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
Panitumumab
Panitumumab 6 mg/kg IV every 14 days.
| Group | Source count |
|---|---|
| Cetuximab | 500 |
| Panitumumab | 499 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cetuximab | 3.3 | Not reported | 3.2 | 3.9 | Not reported |
| Panitumumab | 3.4 | Not reported | 3.2 | 4.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 3.2
- upper Limit
- 3.9
- value
- 3.3
- group Id
- OG001
- lower Limit
- 3.2
- upper Limit
- 4.6
- value
- 3.4
- denoms
- counts
- group Id
- OG000
- value
- 500
- group Id
- OG001
- value
- 499
- units
- Participants
- description
- Time to treatment failure (TTF) is the time from randomization date to date that the decision was made to end the treatment period for any reason; participants who remained in the treatment period at the time of analysis were censored at the date of the last on-study assessment.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
- id
- OG000
- title
- Cetuximab
- description
- Panitumumab 6 mg/kg IV every 14 days.
- id
- OG001
- title
- Panitumumab
- param Type
- MEDIAN
- population Description
- Primary analysis set
- reporting Status
- POSTED
- time Frame
- From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
- title
- Time to Treatment Failure
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice